Theravance Biopharma, Inc.
TBPH
$17.05
-$0.01-0.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.73M | 17.70M | 45.89M | 19.99M | 26.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.73M | 17.70M | 45.89M | 19.99M | 26.20M |
| Cost of Revenue | 4.71M | 5.83M | 7.36M | 8.11M | 10.49M |
| Gross Profit | 16.02M | 11.87M | 38.53M | 11.88M | 15.71M |
| SG&A Expenses | 14.18M | 17.72M | 18.52M | 18.33M | 18.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.89M | 23.55M | 25.88M | 26.45M | 28.92M |
| Operating Income | 1.84M | -5.85M | 20.01M | -6.46M | -2.73M |
| Income Before Tax | -4.79M | -6.47M | 73.07M | -2.89M | 73.21M |
| Income Tax Expenses | 1.11M | -1.54M | 12.04M | -6.50M | 18.37M |
| Earnings from Continuing Operations | -5.90M | -4.93M | 61.02M | 3.62M | 54.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.90M | -4.93M | 61.02M | 3.62M | 54.84M |
| EBIT | 1.84M | -5.85M | 20.01M | -6.46M | -2.73M |
| EBITDA | 2.21M | -5.47M | 20.41M | -6.05M | -2.32M |
| EPS Basic | -0.11 | -0.10 | 1.20 | 0.07 | 1.09 |
| Normalized Basic EPS | 0.06 | -0.03 | -0.64 | -0.04 | 0.91 |
| EPS Diluted | -0.11 | -0.10 | 1.15 | 0.07 | 1.08 |
| Normalized Diluted EPS | 0.06 | -0.03 | -0.61 | -0.03 | 0.90 |
| Average Basic Shares Outstanding | 51.67M | 51.28M | 50.87M | 50.52M | 50.18M |
| Average Diluted Shares Outstanding | 51.67M | 51.28M | 53.05M | 51.91M | 50.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |